Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline (Q87946441)
Jump to navigation
Jump to search
scientific article published on 23 May 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline |
scientific article published on 23 May 2014 |
Statements
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline (English)
Susan Branford
David T Yeung
Wendy T Parker
Leanne Purins
Jodi A Braley
Haley K Altamura
Alexandra L Yeoman
Jasmina Georgievski
Bronte A Jamison
Stuart Phillis
Zoe Donaldson
Mary Leong
Linda Fletcher
John F Seymour
Andrew P Grigg